Mark R. Hake

Mark R. Hake

CFA

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Wait Until Naked Brand Falls to 34 Cents Before Even Thinking About Buying

By Mark R. Hake, CFA

Naked has a cash war chest and a small online business worth $305 million in total, or 34 cents per share. Here's what to do with NAKD stock.

Wells Fargo Stock Can Rise 22% if the Dividend Keeps Increasing

By Mark R. Hake, CFA

Wells Fargo looks too cheap right now. WFC stock is worth at least $60 given new growth in earnings, tangible book value and dividends.

DraftKings’ Q2 Earnings Show the Stock May Be Worth $80-Plus

By Mark R. Hake, CFA

DraftKings' Q2 sales and earnings surprise analysts, pushing up its inherent value. DKNG stock could be worth 56% more at $80.93, assuming it achieves 2025 revenue and margin targets.

Senseonics Could Go Higher, Especially if It Nabs FDA Approval

By Mark R. Hake, CFA

Senseonics looks interesting here, especially with possible FDA approval. SENS stock is worth about 24% more at over $4, or even $6-plus once its CGM rolls out.

The Delta Variant Is a Shot in the Arm for Vaxart’s Pill Vaccine

By Mark R. Hake, CFA

The Delta Covid variant gives Vaxart new life with its oral vaccine and could boost VRXT stock. VXRT stock is worth over 30% more at $13.00 if its Covid pill works, according to sell-side analysts.

Stellar Lumens Looks Like Good Value, Especially If It Matches Ripple’s Gains

By Mark R. Hake, CFA

Stellar Lumens is regaining lost financial ground as prices increase and enjoys growing popularity as a crypto payment network.

Baidu Stock Looks Cheap — Contrarians, Buy Before it Rebounds

By Mark R. Hake, CFA

BIDU stock might drop 20% or more but it looks like good value now. Contrarian investors should start averaging in before it rebounds.

Robinhood Is Unprofitable and Probably Won’t See Net Income Until 2022

By Mark R. Hake, CFA

HOOD stock trades for 155 times 2023 earnings. In 2 years it still won't have a clear path to profitability for any prospective investors.

Virgin Galactic Could Drift Down to $20.86 Before It’s a Bargain

By Mark R. Hake, CFA

Virgin Galactic has fallen from its lofty valuation but will drop further. SPCE stock could drift down another 37.5% before it's a buy.

Blackberry Is Dead in the Water Unless Sales Start to Pick Up

By Mark R. Hake, CFA

Blackberry stock is in a slump but could dig itself out next year if sales revive. BB stock is at full value now given the company's poor growth outlook from its latest Q1 earnings.

Load More